BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Nasdaq/NYSE listing notice — Brainstorm Cell receives Nasdaq delisting notice for failure to meet MVLS minimum

BRAINSTORM CELL THERAPEUTICS INC.

Nasdaq notified BCLI on Jan 15, 2025 that it failed to regain compliance with the $35M MVLS requirement by the Jan 14 deadline.
Unless BCLI appeals by Jan 22, 2025, its common stock will be delisted from the Nasdaq Capital Market at open on Jan 24, 2025.
Company intends to appeal the delisting determination, but no assurance of success or continued listing.
BCLI previously received a 180-day cure period on July 18, 2024 to meet the MVLS rule (Nasdaq 5550(b)(2)).

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

January 15, 2025, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company reque

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

January 15, 2025, the Company received written notice from the Staff of Nasdaq notifying it that the Company failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company requests an appeal of Nasdaq’s determination to delist the Company’s common stock from The Nasdaq Capital Market by January 22, 2025, the Company’s common stock will be delisted from The Nasdaq Capital Market at the opening of business on January 24, 2025. While the Company intends to appeal Nasdaq’s decision, no guarantee can be provided that it will be successful in doing so and t

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-003777

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.